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PRECLINICAL STUDIES
euregulin-1/erbB-Activation Improves
ardiac Function and Survival in Models
f Ischemic, Dilated, and Viral Cardiomyopathy
ifu Liu, PHD,* Xinhua Gu, MD,* Zhaoming Li, PHD,* Xinyan Li, MD, PHD,* Hui Li, MD,*
ianjie Chang, MD,* Ping Chen, MD,* Jing Jin, BSC,* Bing Xi, MSC,* Denghong Chen, BSC,*
onna Lai, PHD,† Robert M. Graham, FAA, MD,† Mingdong Zhou, PHD*
hanghai, China; and Sydney, Australia
OBJECTIVES We evaluated the therapeutic potential of a recombinant 61-residue neuregulin-1 (beta2a isoform)
receptor-active peptide (rhNRG-1) in multiple animal models of heart disease.
BACKGROUND Activation of the erbB family of receptor tyrosine kinases by rhNRG-1 could provide a
treatment option for heart failure, because neuregulin-stimulated erbB2/erbB4 heterodimeriza-
tion is not only critical for myocardium formation in early heart development but prevents severe
dysfunction of the adult heart and premature death. Disabled erbB-signaling is also implicated in
the transition from compensatory hypertrophy to failure, whereas erbB receptor-activation
promotes myocardial cell growth and survival and protects against anthracycline-induced
cardiomyopathy.
METHODS rhNRG-1 was administered IV to animal models of ischemic, dilated, and viral cardiomyopathy,
and cardiac function and survival were evaluated.
RESULTS Short-term intravenous administration of rhNRG-1 to normal dogs and rats did not alter
hemodynamics or cardiac contractility. In contrast, rhNRG-1 improved cardiac performance,
attenuated pathological changes, and prolonged survival in rodent models of ischemic, dilated, and
viral cardiomyopathy, with the survival benefits in the ischemic model being additive to those of
angiotensin-converting enzyme inhibitor therapy. In addition, despite continued pacing,
rhNRG-1 produced global improvements in cardiac function in a canine model of pacing-induced
heart failure.
CONCLUSIONS These beneficial effects make rhNRG-1 promising as a broad-spectrum therapeutic for the
treatment of heart failure due to a variety of common cardiac diseases. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.0572006;48:1438–47) © 2006 by the American College of Cardiology Foundation
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1he erbB family of receptor tyrosine kinases and their
igands, neuregulins (NRGs), are critical involved not only
n cardiac development but also in the maintenance of
tructural and functional integrity of the adult heart (1–3).
rbB2 (Her2/neu) functions as a non–ligand-binding, pre-
ctivated co-receptor (4) and in the myocardium het-
rodimerizes with ErbB4 (Her4), upon activation by
RG-1; the latter is expressed by the endocardium and
See page 1448
ndothelium of the cardiac microvasculature (5). Initial
vidence for a functional role of the NRG/erbB signaling
ystem in adult heart came from trials of the monoclonal
ntibody, trastuzumab (Herceptin), in patients with erbB2-
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006, accepted May 30, 2006.verexpressing breast cancers (6). Downregulation of erbB2
y Herceptin resulted in a low incidence of cardiac dysfunc-
ion when used as monotherapy but, importantly, the
evelopment of cardiomyopathy in almost 30% of patients
hen combined with an anthracycline. In addition, whereas
rbB2-deficient conditional mutant mice are viable at birth,
dult animals develop severe dilated cardiomyopathy with
all thinning and decreased contractility, leading to prema-
ure death from heart failure (7).
ErbB2/4 receptors downregulate with the onset of heart
ailure in animals with pressure-overload hypertrophy, in-
icating involvement of disabled erbB signaling in the
ransition from compensatory hypertrophy to failure (8). In
ontrast and consistent with the latter findings in animals,
xpression of erbB receptors increases in heart failure
atients subjected to mechanical unloading, particularly
hose with ischemic cardiomyopathy (9). In adult cardiomy-
cytes, NRG-1 enhances sarcomere organization, protects
gainst myofibrillar disarray (10), and unlike other hypertro-
hic stimuli such as angiotensin II or interleukin-1beta/
FNgamma, promotes cell-survival rather than death (1,5,11).
Despite these pleiotropic “cardiotonic” effects of NRG-
/erbB-activation, its therapeutic potential has not been
valuated. We show here that, in each of 4 distinct models
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October 3, 2006:1438–47 Neuregulin-1 Improves Heart Function and Survivalf severe left ventricular (LV) failure, short-term adminis-
ration of a recombinant receptor-active NRG-1 peptide-
ragment significantly improves or protects against deterio-
ation in myocardial performance and, importantly, in a
odent model of ischemic cardiomyopathy, prolongation of
urvival is additive to that observed with converting enzyme
nhibitor-treatment.
ETHODS
roduction and activity of rhNRG-1. Deoxyribonucleic
cid encoding the epidermal growth factor-like domain of
uman NRG-1 (beta2a isoform; residues Ser177-Glu237)
as polymerase chain reaction (PCR)-amplified (Fig. 1A),
nd the resulting E. coli-expressed 61-residue peptide
rhNRG-1) was purified by sequential ion-exchange and
ydrophobic chromatography (final purity 95%, as deter-
ined by sodium dodecyl sulfate polyacrylamide gel elec-
rophoresis [SDS-PAGE]) (Fig. 1B). Primary cultures of
at neonatal cardiomyocytes were used to evaluate the
ctivity (erbB4 phosphorylation) of the purified protein
Fig. 1C), as previously described (12). Activity of
hNRG-1 was also evaluated in vivo by IV bolus adminis-
ration to mice, rats, and dogs, as detailed in Figure 1, and
his response was used in dose-finding studies to determine
he doses of rhNRG-1 required in vivo for the subsequent
emodynamic studies.
nfarct model. Sprague Dawley rats (200 to 250 g, Animal
enter of Fudan University, Shanghai, China) were anes-
hetized (ketamine hydrochloric acid [HCl], 100 mg/kg,
P), and the LV was infarcted by ligation of the left anterior
escending coronary artery (LAD), as described (13). Sham-
perated animals were similarly treated except that the suture
round the LAD was left untied; rhNRG-1 (10 g/kg/day,
V, for 5 or 10 days) or vehicle (0.2% albumin/phosphate
uffered saline, pH 6.0) was administered as indicated in
igure 2. Sham-operated animals received no treatment. An-
Abbreviations and Acronyms
cTnI  cardiac troponin I
CV-B3  Coxsackie virus B3
EF  ejection fraction
ERK  extracellular signal-regulated kinase
FS  fraction of shortening
LAD  left anterior descending coronary artery
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic diameter
LVEDP  left ventricular pressure development at
end-diastole
LVESD  left ventricular end-systolic diameter
LVESP  left ventricular pressure development at
end-systole
MEK  mitogen-activated protein /ERK
NRG  neuregulin
rhNRG-1  recombinant human neuregulin-1
TCID50  50% tissue culture infectious doseiotensin I and II, aldosterone levels, and plasma renin vctivity were determined by radioimmunoassay (Institute of
eijing North Biotechnology), in plasma isolated from
lood samples obtained at the time of the final hemody-
amic study in sham-operated and LAD-ligated animals
reated with rhNRG-1 or vehicle for 5 days. All animal
tudies were approved by the Animal Care and Use Com-
ittee, Shanghai City, China.
rug-induced cardiomyopathy model. Doxorubicin was
dministered to 2 groups (n  20/group) of Sprague Dawley
ats (300 to 350 g), as detailed in the text. Simultaneously, 1
roup received rhNRG-1 (20 g/kg/day, IV, for 5 days), and
nother, vehicle alone. A 3rd group (n  20) served as
ntreated control subjects. Hemodynamics and cardiac pa-
hology were evaluated after 4 weeks. Myocardial cell
amage was assessed from serum cardiac troponin I (cTnI)
evels (Optus Plus Immunoassay System, Boehringer Diag-
ostics, Germany).
yocarditis models. In vitro, trypsin-digested Sprague
awley neonatal rat cardiomyocytes were cultured in 24-
ell plates at a density of 5  105 cells/well with 20% fetal
ovine serum in Eagle’s Minimum Essential Medium at
7°C, 5% carbon dioxide. After 18 h, cells were infected
ith Coxsackie virus B3 (CV-B3; Nancy strain) (Institute
f Cardiovascular Disease, Zhongshan Hospital, Fudan
niversity) for 1 h. Viral titers were expressed as the 50%
issue culture infectious dose (TCID50) (14). Cells incu-
ated with medium alone were used as control subjects. The
V-B3–infected cells were then washed with virus-free
edium and divided into 2 groups: 1 treated with rhNRG-1
100 ng/ml), and 1 with vehicle. Cells were then cultured
or 3 to 5 days and evaluated for cTnI release into the
ulture medium. Each group consisted of 5 replicate wells.
In vivo, 4-week-old male Balb/c mice (Animal Center,
udan University) were inoculated with CV-B3 (1  104
CID50 in 0.2 ml virus solution, IP) or were untreated
timed control subjects). The CV-B3–infected mice were
reated with rhNRG-1 (30 g/kg/day, IV, for 5 days) or
ith vehicle. Seven days later, echocardiography was per-
ormed, and blood was sampled for cTnI levels. The hearts
ere then harvested for histological evaluation and deter-
ination of viral titers as described (14), except using Hep2
ells.
hronic rapid pacing model. Beagle dogs (8 to 10 kg)
ere anesthetized with sodium pentobarbital (25 mg/kg,
V). A unipolar pacing lead (Model 4023-58 cm,
edtronic, Minneapolis, Minnesota) was inserted into the
ight ventricular apex through the jugular vein under X-ray
uidance and connected to a programmable pacemaker
Prevail 8086, Medtronic) that was implanted into a sub-
utaneous pocket. The dogs were allowed to recover for 7 to
0 days before experimentation. A control, sham group had
he pacing lead implanted, but the pacemaker was not
ctivated. Two experimental groups were paced at 230
eats/min for 3 weeks, at which time 1 received rhNRG-1
3 g/kg/day, IV, for 5 days) and the other received only
ehicle. Pacing was continued during these 5 days of
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amics and cardiac contractility were evaluated as detailed
n the following section.
emodynamics, echocardiography, and contractility
tudies. Arterial pressure and heart rate were determined
y micromanometry (15) in rats and dogs anesthetized with
odium pentobarbital (30 mg/kg, IP, or 25 mg/kg, IV,
espectively). Echocardiography was performed on rats and
igure 1. rhNRG-1 construction, synthesis, and erbB-activating activity. (A)
he immunoglobulin-like (IgG-L), and epidermal growth factor-like (EGF-L
ytoplasmic tail (CT). The construct used here (designated receptor-active 61
egion of NRG-1, encompassing residues Ser177 to Glu237, followed by a sto
n E. coli from a T7 promoter (arrow). (B) Sodium dodecyl sulfate polyacrylam
he resulting 6.7 kDa Coomassie-stained rhNRG-1 protein at a purity 95%
timulated erbB2 and erbB4 phosphorylation in cultured neonatal cardiomyoc
ECD) (12) were used as negative and positive control subjects, respectively. (D
nti-erbB4 antisera) and immunoblotting (IB, anti–phospho-tyrosine, p-Try,
ysates prepared from the hearts of mice given 10 g/kg rhNRG-1, IV, 10 or
s also shown (lower panel). (E) In vivo activation of extracellular signal-regu
B of lysates prepared from the hearts of mice given rhNRG-1, 10 g/kg IV,
upper panel; 42 and 44 kD isoforms are shown) and anti–holo-ERK- (lower
he p-ERK bands in (E) were quantitated by PhosphorImager analysis an
ime-dependent increase in p-ERK44 is shown. Increased pERK1/2 mitogen
bserved in the lysates of the hearts of rats (G) and dogs (H) 10 min after boogs anesthetized with ketamine HCl (100 mg/kg, IP) or oodium pentobarbital (25 mg/kg), respectively, and on
mmobilized conscious mice, as described previously (15).
he LV was imaged in the short-axis view at the mid-
apillary muscle level, and M-mode measurements of left
entricular end-diastolic diameter (LVEDD) and left ven-
ricular end-systolic diameter (LVESD) were recorded and
ransferred on-line to a computer for analysis. Ejection
raction (EF) and fraction of shortening (FS) were measured
atic of full-length membrane-bound form of neuregulin (NRG)-1 showing
ns of its extracellular domain as well as its transmembrane domain (TM) and
ue recombinant neuregulin-1 peptide [rhNRG-1]), encoding the EGF-like
n (indicated) and a stroke volume 40 poly A tail (open box), was expressed
el electrophoresis (15%) fractionation of E. coli-expressed rhNRG-1 showing
t lane) and molecular weight standards (right lane). (C) Purified rhNRG-1
ells stimulated with vehicle or with full-length NRG-1 extracellular domain
ivo activity of rhNRG-1 was similarly evaluated by immunoprecipitation (IP,
erum [Sigma Biochemical, St. Louis, Missouri] or anti-erbB4 antiserum) of
n before being killed (upper panel). Holo-erbB4 visualized by anti-erbB4 IB
kinase (ERK)1/2 mitogen-activated protein kinases was evaluated by IP and
30, 90, and 270 min before being killed, with anti–phospho-ERK- (p-ERK)
l) specific antibodies (Santa Cruz Biotechnology, Santa Cruz, California). (F)
ressed as the fold-increase (stimulation) over the basal (0 min) levels. The
ted protein kinases (upper panels; lower panels show holo-ERK) were also
administration of rhNRG-1, 10 and 3 g/kg, respectively.Schem
) regio
-resid
p codo
ide g
(lef
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antis
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pane
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October 3, 2006:1438–47 Neuregulin-1 Improves Heart Function and Survivaligure 2. rhNRG-1 improves echocardiographically determined cardiac dimensions and performance after coronary artery ligation. (Upper panel)
iagrammatic schema of treatment protocols. (Lower panel) Cardiac dimensions and performance. Protocol I (panels A to D): 1 week after left anterior
escending coronary artery (LAD) ligation, the rats received no treatment (sham-operated group, black bars, n  10), vehicle (red bars, n  12), or
hNRG-1 (10 g/kg IV daily, blue bars, n  13) for 5 days (Day 5 group) or 10 days (Day 10 group) with echocardiographic evaluation at the end of
hese treatment periods. Protocol II (panels E to H): as for Protocol I, except that vehicle (n  15) or rhNRG-1 (n  30) treatment was commenced 2
onths after LAD ligation and continued for 5 days (Day 5 group) or 10 days (Day 10 group). The sham-operated group received no treatment (n  20).
VEDD left ventricular end-diastolic diameter; LVESD left ventricular end-systolic diameter; EF ejection fraction; FS fraction shortening; other
bbreviations as in Figure 1. *p  0.05 and **p  0.01 versus vehicle.
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Neuregulin-1 Improves Heart Function and Survival October 3, 2006:1438–47ogs was obtained by Doppler echocardiography. This
llowed cross-sectional area of the aortic root, LV ejection
ime, and mean aortic flow velocity to be determined, which
ere then used to calculate stroke volume and thus cardiac
utput, given that cardiac output  stroke volume  heart
ate.
istological analyses. Ten serial transverse sections of
ormalin-fixed and paraffin-embedded rat heart were cut
rom each of 3 regions: apex, mid-ventricle, and just below
he atrioventricular junction. Sections were hematoxylin and
osin (H & E)-stained and examined under light micros-
opy ( 10) by an experienced investigator blinded to the
reatments, for myocardial lesions induced by doxorubicin
cytoplasmic vacuolization and/or myofibrillar loss) or viral
nfection (necrosis and inflammation). Findings were
raded with a semiquantitative score from 0 to 4 (0  no
athological changes; 1  lesions involving 25% of the
eld; 2  lesions involving 25% to 50%; 3  lesions
nvolving 50% to 75%; and 4  lesions involving 75% to
00%). Representative views were photographed. Capillary
ensity (vessels/mm2) in fibrotic areas was also determined
y counting 3 slides and 3 views per slide.
tatistical analyses. Data are presented as mean 1 SEM.
tatistical comparisons (p  0.05 was considered signifi-
ant) were by 1-way ANOVA followed by Tukey’s post hoc
nalysis. Cumulative survival data was evaluated by Kaplan-
eier nonparametric regression analysis and the Mantel-
ox log rank test. Statistical analyses were performed with
igure 3. rhNRG-1 improves hemodynamics after LAD ligation. Treatmen
wice daily by gavage for the duration of the study), or the same doses of
AD ligation, and hemodynamic studies were performed 33 weeks thereaft
B) mean arterial pressure (MAP); (C) LV pressure (LVP) at end-systole (
open bars) and dP/dt (filled bars), rate of contraction and relaxation, respec
roups). *p  0.05; **p  0.01 versus vehicle; p  0.01 versus captopril. Othhe SPSS software (SPSS Inc., Chicago, Illinois). All data
rom hemodynamic and echocardiographic recordings and
ubsequent analyses were made without knowledge of
reatments.
ESULTS
RG-1 peptide and activity. We synthesized a 61-residue
eptide (rhNRG-1) corresponding to the epidermal growth
actor-like domain of human NRG-1 and containing 3
isulfide bonds and used it to activate erbB signaling (Fig.
). This peptide retains the binding and erbB-activating
roperties of the 637 amino acid parent protein and can be
ynthesized recombinantly in high yield. Correct folding
nd disulfide bond-connectivity (17) were confirmed by
eptide digestion and mass spectrometry (data not shown)
nd are evident from the ability of rhNRG-1 to stimulate
rbB2/4 phosphorylation in vitro and in vivo (Fig. 1).
hNRG-1 signaling and effect on sarcomere organiza-
ion. We also demonstrated, consistent with the enhanced
yofibrillogenesis observed by Saywer et al. (10) and Baliga
t al. (11), with NRG-1 treatment of cultured cardiomyo-
ytes, that sarcomere organization was enhanced with
hNRG-1 (data not shown). This cardiomyocyte response
ould be blocked by the mitogen-activated protein/
xtracellular signal-regulated kinase (ERK) (MEK)-1 in-
ibitor, PD98059, indicating involvement of the ERK1/2
ignaling pathway but not by the PI-3 kinase inhibitor,
th vehicle, rhNRG-1 (10 g/kg, IV, daily for 5 days), captopril (2.5 mg/kg
G-1 and captopril (capt.) in combination were commenced 1 week after
am-operated animals (Sham) received no treatment. (A) Heart rate (HR);
SP, open bars), and end-diastole (LVEDP, filled bars); and (D) dP/dtts wi
rhNR
er. Sh
LVEtively (n  10 for sham and vehicle groups; n  20 for each of the other
er abbreviations as in Figures 1 and 2.
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October 3, 2006:1438–47 Neuregulin-1 Improves Heart Function and Survivalortmannin (data not shown). Consistent with these in
itro findings, intravenous administration of rhNRG-1 in
ice, rats, and dogs activated cardiac ERK1/2 (p42/44
itogen-activated protein kinases) (Figs. 1E–1H).
at myocardial ischemia model. Myocardial infarction,
nduced here by LAD ligation, is widely used to produce a
odel of LV dysfunction. Impaired cardiac performance is due
o loss of myocardium and progressive remodeling character-
zed by LV dilatation (increased LV dimensions), contractile
ysfunction (reduced EF percent and percent FS), and in-
reased filling pressure (LVEDP) (18), as evident here in
ham-operated versus vehicle-treated animals subjected to
AD ligation (Figs. 2 and 3, protocol I). rhNRG-1, given 1
eek after LAD ligation, significantly attenuated the dysfunc-
ion in all parameters evaluated (Figs. 2A and 2B, protocol I).
lthough this attenuation was less marked if rhNRG-1-
reatment was delayed until 2 months after LAD ligation,
mprovements in cardiac performance (LVESD, EF, and FS)
Figs. 2E and 2F, protocol II) were still evident.
In additional groups of animals subjected to LAD liga-
ion followed, 1 week later, by rhNRG-1 (10 g/kg/day for
days) or vehicle, histological analysis revealed no difference
n infarct size, which averaged 30% to 35%; but consistent
ith an angiogenic effect of erbB receptor-activation (19),
apillaries were more abundant in the fibrotic peri-infarct
egions in the rhNRG-1-treated group (vessels/mm2: 6.5 
.2, vehicle-treated; 10.1  3.0, rhNRG-1-treated, p 
.01). Moreover, cardiac failure, evident by activation of the
enin-angiotensin-aldosterone axis, was attenuated by
hNRG-1 treatment (Table 1).
To evaluate the effects of erbB receptor-activation on
urvival, we compared LAD-ligated animals given
hNRG-1 (10 g/kg/day for 5 days) with those given either
ehicle alone, the angiotensin-converting enzyme inhibitor,
aptopril (2.5 mg/kg twice daily for the duration of the
tudy), or combined captopril plus rhNRG-1 treatment. We
ommenced treatment 1 week after LAD ligation. In
ehicle-treated animals surviving 172 days from the com-
encement of treatment, cardiac dysfunction was evident
able 1. rhNRG-1 Inhibits Renin Angiotensin System-Activatio
Parameter/Treatment (n) Ang I (ng/ml) Ang
O (6) 8.1  0.7* 0.
ehicle (6) 10.6  0.7 1.
hNRG-1 (6) 7.4  0.9* 0.
p  0.05 versus vehicle.
Ang  angiotensin; rhNRG-1  receptor-active 61-residue recombinant neureg
able 2. rhNRG-1 Given 2 Months After LAD Ligation Impro
Parameter/Treatment (n)*
HR
(beats/min)
LVESP
(mm Hg)
L
(m
O (10) 377.9  12.9 139.9  2.9† 1
ehicle (8) 337.2  17.5 86.6  3.5 11
aptopril (10) 328.8  19.1 85.4  5.0 8.1
hNRG-1 (11) 363.3  12.6 121.8  5.2†§ 6Treatments as per protocols II, Figure 2. †p  0.01 versus vehicle. ‡p  0.05. §p  0.05
Abbreviations as in Figure 3 and Table 1.rom marked impairment of LV pressure development at
oth end-systole (LVESP, 27%) and end-diastole
LVEDP, 43%), reduced rates of contractility (dP/dt)
46%) and relaxation (dP/dt) (44%), and lower arterial
ressure (21%) (Fig. 3). In contrast, changes in all these
arameters were significantly less marked in animals treated
ith rhNRG-1 or combined therapy but not in those
eceiving captopril alone (Fig. 3). In a related study in which
he initiation of treatment was delayed until 2 months after
AD ligation and the animals evaluated 84 days later, we
bserved similar hemodynamic responses (Table 2). In
ddition to these favorable cardiovascular responses, survival
as markedly improved with rhNRG-1 or captopril (Figs. 4A
nd 4B), and these survival-effects were additive in animals
eceiving combined therapy (Fig. 4A).
Compared with these effects in rats with myocardial
nfarction, administration of rhNRG-1 to normal rats, at a
ose of 10 g/kg/day, IV, for 5 days, had no effect on
chocardiographically determined LVESD, LVEDD, EF,
r percent FS (Table 3).
oxorubicin cardiomyopathy model. Anthracyclines,
uch as doxorubicin, are well-characterized cardiotoxic che-
otherapeutic agents. Myocardial injury is associated with
yofibrillar disarray and contractile abnormalities (10,11).
dministration of doxorubicin (3.3 mg/kg/week, IV, for 4
eeks) to rats induced marked cardiac dysfunction (im-
aired dP/dt and LV pressure generation) (Table 4) as well
s myocardial cell damage, evident both histologically (Fig.
and Table 4) and biochemically (increased plasma cTnI
evels) (Table 4). These changes were prevented
Fig. 5, Table 4) and survival markedly improved (Fig. 4) in
nimals treated concomitantly with rhNRG-1 (20 g/kg/
ay, IV, for 7 days).
yocarditis models. Infections with enteroviruses, such as
V-B3, are a common cause of acute myocarditis that can
ead to heart failure and dilated cardiomyopathy (20). Both
irect viral cytopathic effects and host cellular immune
esponses play a role in disease pathogenesis (21). We
bserved cell damage in neonatal rat cardiomyocytes in-
e to LAD Ligation
ng/ml) Aldosterone (ng/ml) PRA (ng/ml/h)
0.12* 1.1  0.3* 1.3  0.1*
0.24 1.7  0.1 3.5  0.7
0.12* 1.0  0.1* 1.3  0.5*
peptide; PRA  plasma renin activity; SO  sham operated.
emodynamics
P
g)
dp/dt
(mm Hg/s)
dp/dt
(mm Hg/s)
MAP
(mm Hg)
.9† 7,354.0  375.6† 5,453.8  352.9† 104.5  3.1†
.2 4,142.3  170.8 3,019.8  228.7 80.9  8.12
.2‡ 4,226.1  199.5 2,875.8  209.7 63.7  3.1‡
.8† 6,115.4  283.2†§ 4,137.9  212.6†§ 99.4  2.4§n Du
II (
56 
37 
64 ves H
VED
m H
.5  1
.9  1
0  1
.3  0versus captopril.
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ot shown) and from increased cTnI release (n  5, 49 
ng/ml), as compared with vehicle-treated control-cultures
n  5, 25  4 ng/ml, p  0.01). These effects were
ttenuated in cells treated with both virus and rhNRG-1
100 ng/ml for 5 days) (n  5, cTnI: 33  3 ng/ml, p 
.01 vs. virus-infected). Next we investigated whether this
rotective effect is also operative in vivo. Consistent with the
nduction of myocarditis, infection of mice with CV-B3
roduced marked lymphocytic infiltration of the myocar-
ium (Fig. 5) as well as histological (Table 4) and biochem-
cal (increased plasma cTnI levels) evidence of myocardial
amage, LV dilatation (increased LVESD and LVEDD),
nd impaired cardiac function (decreased EF and percent
S) (Table 4). rhNRG-1 (30 g/kg/day for 5 days) not only
rotected against these histological (Fig. 5, Table 4), bio-
hemical (decreased cTnI levels), and echocardiographically
igure 4. Neuregulin-1 improves survival of rats subjected to myocardial infa
3 myocarditis (d). Treatments indicated were commenced 1 week (a; n 51
nce weekly for 4 weeks) (c; n  20) or Coxsackie B3 (0.2 ml virus solution,
eceptor-active 61-residue recombinant neuregulin-1 peptide (rhNRG-1) was
or the doxorubicin-treated rats that received 20 g/kg/day for 7 days. Captopr
umulative survival curves of the sham-operated (SO) or untreated control s
lue), Capt.-treated (green), or vehicle-treated (red) animals, respectively, are
hNRG-1 or Capt. versus vehicle, p  0.02; (c) rhNRG-1 versus vehicle, p 
able 3. rhNRG-1 Does Not Alter Echocardiographically
etermined Cardiac Dimensions or Function in Normal Rats
Parameter/Treatment* rhNRG-1 (n  10) Vehicle (n  10)
VEDD (cm) 0.56  0.04 0.53  0.03
VESD (cm) 0.22  0.03 0.20  0.02
F (%) 93.0  2.00 94.4  1.50
S (%) 60.6  3.70 63.5  3.40
rhNRG-1 (10 g/kg, IV) or vehicle was given daily for 5 days, and thenh
chocardiography was performed.
Abbreviations as in Figure 2.etermined changes in EF percent, percent FS, LVEDD,
nd LVESD (Table 4) but significantly improved survival
Fig. 4). Moreover, the CV-B3 titer was reduced in the
hNRG-1 mice (Table 4), consistent with reduced inflam-
ation with NRG treatment (22).
hronic pacing model. Compared with unpaced control
sham) animals, those paced at 230 beats/min for 3 weeks
eveloped heart failure, as evidenced by reductions in EF
nd cardiac output of approximately 50% and 30%, respec-
ively (Fig. 6). In addition, in the animals treated only with
ehicle, pacing resulted in significant increases in LVEDP
averaging 25 mm Hg), falls in mean arterial pressure of
pproximately 25 mm Hg, and reductions in both dP/dt
nd dP/dt (Fig. 6). Despite continued pacing, treatment
ith rhNRG-1 (3 g/kg/day, IV, for 5 days) improved
VEDP by more than 25% (from 27.7 to 20.5 mm Hg) and
VESP by more than 35% (from 98.7 to 133.2 mm Hg)
ompared with the vehicle-treated group (Fig. 6). Cardiac
ontractility and relaxation were also significantly improved,
y 47% (dP/dt: from 1,740 to 2,558 mm Hg/s) and 55.7%
dP/dt: from 1,107 to 1,723 mm Hg/s), and echocar-
iographically determined percent EF increased by 78%
from 24.6% in the vehicle-treated to 43.8% in the rhNRG-
-treated group) (Fig. 6). By contrast to these effects in dogs
ith pacing-induced heart failure, acute bolus administra-
ion of rhNRG (3 g/kg/day, IV, for 5 days) in normal dogs
(a and b), doxorubicin-induced cardiomyopathy (c), or mice with Coxsackie
months (b; n 20) after LAD ligation or when doxorubicin (3.3 mg/kg, IV,
% tissue culture infectious dose  104) (d; n  20) was administered. The
at 10 and 30 g/kg/day IV for 5 days to rats and mice, respectively, except
pt.) was given at 2.5 mg/kg twice daily by gavage for the duration of the study.
ts (black), rhNRG-1-treated (dark blue), rhNRG-1  Capt.-treated (light
. (a) rhNRG-1 versus vehicle, p 0.028; rhNRG-1 versus Capt. p ns; (b)
001; (d) rhNRG-1 versus vehicle, p  0.02.rction
) or 2
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elaxation (dP/dt or dP/dt), recorded continuously over
0 min after administration (Table 5).
igure 5. The receptor-active 61-residue recombinant neuregulin-1 peptide
rhNRG-1) improves doxorubicin-induced and Coxsackie B3 (CV-B3)-
nduced myocardial pathology. Transverse sections of myocardium obtained
fter: no treatment (control) (a), doxorubicin (3.3 mg/kg, IV, once weekly for
weeks) plus vehicle (b), or doxorubicin  rhNRG-1 (20 g/kg/day for the
rst 7 days) (c) treatment of rats; or no treatment (control) (d ), CV-B3
nfection of mice  vehicle (e), or CV-B3  NRG-1 (30 g/kg/day, IV, for
days) (f ). Staining: hematoxylin and eosin; magnification: 10; white space
able 4. rhNRG-1 Protects Against Doxorubicin and Coxsackie
Treatment*/Parameter Control (n  10) Doxo
dP/dt (mm Hg/s) 6,235  150†
dP/dt (mm Hg/s) 4,590  355†
VESP (mm Hg) 153.3  4.9†
VEDP (mm Hg) 4.6  2.3†
Tnl (ng/ml) 0.43  0.03†
istopathology score 0  0†
Control (n  10) Coxsack
VESD (cm) 0.07  0.002†
VEDD (cm) 0.18  0.003
F (%) 92.5  0.90†
S (%) 59.2  1.20†
Tnl (ng/ml) 3.3  1.10†
istopathology score 0  0†
og TCID50 0  0†
Doxorubicin, Coxsackie B3, and rhNRG-1 were administered as detailed in Method
r Coxsackie B3  vehicle. ‡p  0.05 versus doxorubicin  vehicle or Coxsackie B
cTnl  cardiac troponin 1; other abbreviations as in Figure 2.c
ar (a)  50 m. Arrows indicate areas of necrosis (b) and lymphocytic
nfiltration (e), which are much less apparent with rhNRG-1 treatment (c, f ).ISCUSSION
e and others have shown that in vitro erbB receptor-
ctivation promotes myofibrillar organization in the face of
erum-starvation and, as we show here, limits the cyto-
athic effects of Coxsackie infection. In addition, in each
f 4 different models of LV failure, erbB receptor-
ctivation improves both cardiac performance and sur-
ival. In the rat ischemia model, favorable cardiovascular
esponses do not occur acutely (within minutes), as would
e expected with agents that activate protein kinase A or
ther inotropic pathways. Nevertheless, the early diver-
ence of the cumulative survival curves indicates that
mprovements in cardiac function begin to occur within a
ew days of commencing treatment. Moreover, despite a
hort circulating half-life (approximately 30 min; unpub-
ished data), rhNRG-1-induced improvements in cardiac
unction and survival were sustained for at least 60 to 80
ays after treatment was discontinued. After this, decre-
ents in survival began to parallel those seen with vehicle-
reatment.
In contrast to captopril, arterial pressure was well main-
ained with rhNRG-1 (Fig. 3). This suggests that these 2
gents have distinct modes of action, and in support of this
otion is the finding that combined treatment was superior
o either agent alone, both in terms of improvements in
ardiac performance and survival. Potential therapeutic
ffects of erbB receptor-activation to improve cardiac per-
ormance by promoting organization of sarcomere structure,
ell integrity, and cell-cell adhesion (10,11) as well as
uppress apoptotic pathways (5) and enhance angiogenesis
19) (evident here by the increase in infarct-region capillary
ensity, which might contribute to enhanced cardiac func-
ion by improving LV compliance) are also likely distinct
rom the mechanisms underlying the favorable effects of
ther agents presently used for heart failure. Calcium
nduced Cardiac Dysfunction and Myocardial Cell Damage
in  vehicle (n  8) Doxorubicin  rhNRG-1 (n  10)
,675  182 6,107  148†
,154  243 4,323  162†
84.7  7.9 130.2  5.7†
15.5  1.2 4.8  2.2†
0.51  8.4 0.68  0.24†
1.44  0.43 0.11  0.04†
 vehicle (n  10) Coxsackie B3  rhNRG-1 (n  10)
14  0.01 0.09  0.004†
21  0.01 0.19  0.002
.1  4.0 90.2  1.00†
.2  2.9 55.7  0.90†
.4  3.9 8.0  1.92†
75  0.11 0.58  0.08†
.0  0.54 1.4  0.16‡
hemodynamics were evaluated after 4 weeks. †p  0.01 versus doxorubicin  vehicle
ehicle.B3-I
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etabolic demand.
Although increased mortality was reported in mice given
RG-1 (23), the dose administered was almost 100 times
igure 6. The receptor-active 61-residue recombinant neuregulin-1 pepti
ailure. Three groups of animals were studied (n  6/group), as detailed in
n this group were not paced. The 2 experimental groups were paced at 2
g/kg/day, IV, for 5 days). Pacing was continued during the treatment pe
LV) end-systolic (white bars) and end-diastolic pressures (black bars) (C
lack bars) (D) were determined after the treatment periods (i.e., after 26 d
etermined on 3 occasions: 1) after the recovery period immediately before
) after 5 days of vehicle or rhNRG-1 treatment (blue bars). Pacing
easurements. *p  0.05; **p  0.01 versus vehicle.
able 5. rhNRG-1 Does Not Alter Hemodynamics or Cardiac C
Time (min) HR (beats/min) LVPmax (mm Hg)
0 116.1  9.5 128.7  10.6
1 113.6  8.6 130.0  10.4
3 113.6  8.4 128.1  10.1
5 113.6  9.5 136.4  8.0
0 112.8  9.1 138.0  9.2
5 116.5  10.0 138.0  7.8
0 116.2  9.0 129.4  10.8
5 116.2  8.6 126.0  11.2
0 117.5  10.1 127.3  9.3
5 116.5  10.6 125.0  11.5
0 122.0  9.7 126.9  13.7
eceptor-active 61-residue recombinant neuregulin-1 peptide (rhNRG-1) (3 g/kg)
HR  heart rate; LVPmax and LVPmin  maximum and minimum left ventricular
espectively.igher than the rhNRG-1 used here, the isoform (beta1)
iffered, and NRG was given by continuous infusion over a
rolonged period (14 days). More importantly, with highly
urified cyclic guanosine monophosphate (current Good
NRG-1) improves cardiac functions in dogs with pacing-induced heart
hods. The control group (sham) had a pacing lead implanted, but animals
ats/min for 3 weeks and then treated with either vehicle or rhNRG-1 (3
. Heart rate (HR) (A), mean arterial pressure (MAP) (B), left ventricular
d rates of LV contraction (dP/dt, white bars) and relaxation (dP/dt,
f pacing). Ejection fraction (EF, percent) (E) and cardiac output (F ) were
g was commenced (black bars), 2) after pacing for 3 weeks (red bars), and
iscontinued at the time of the hemodynamic and cardiac contractility
actility in Normal Dogs
min (mm Hg) dp/dt (mm Hg/s) dp/dt (mm Hg/s)
.48  2.58 2,867.1  135.8 2,655.2  241.2
.38  2.08 2,941.9  108.8 2,758.8  274.0
.08  1.90 2,930.3  99.0 2,629.4  268.6
.37  1.58 3,609.1  430.0 2,784.0  309.7
.27  1.46 3,729.6  358.4 2,901.5  213.0
.54  1.74 3,604.2  337.8 2,880.5  267.2
.23  1.61 3,182.7  293.2 2,565.9  320.3
.62  1.86 3,028.6  255.0 2,528.9  331.1
.27  2.07 3,008.0  176.2 2,656.4  283.1
.35  1.95 2,904.4  226.1 2,677.1  287.2
.76  2.18 2,944.0  326.3 2,598.4  333.6
iven by IV bolus to 6 dogs.de (rh
Met
30 be
riods
), an
ays o
pacinontr
LVP
4
4
4
3
2
1
2
1
1
2
2
was g
pressure, respectively; dP/dt, dP/dt  rates of LV contractility and relaxation,
M
o
s
c
h
p
s
m
r
e
c
c
e
c
P
a
p
a
t
a
y
c
p
J
v
w
t
c
t
u
C
s
a
r
p
t
a
s
t
r
e
a
a
v
A
T
N
R
Z
S
m
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
1447JACC Vol. 48, No. 7, 2006 Liu et al.
October 3, 2006:1438–47 Neuregulin-1 Improves Heart Function and Survivalanufacturing Practice)-prepared rhNRG-1, no deaths or
ther major side effects were observed in formal toxicology
tudies in mice, rats, and Rhesus monkeys or in a phase 1
linical trial that we have completed involving 80 normal
umans (Liu et al., data to be reported in a separate
ublication). Also, malignant transformation was not ob-
erved in any female rats given injections of rhNRG-1 (3
g/kg/day) into breast tissue for 1 month (data not shown).
With the cardiomyopathy and myocarditis models,
hNRG-1 seems to limit myocardial-cell damage, as was
vident by reduced troponin I release and histological
hanges, and in both models divergence in the survival
urves from those of the vehicle-treated groups occurred
arly and was sustained. Protection against anthracycline
ardiotoxicity involves NRG-1-mediated activation of the
I3-kinase pathway, which limits apoptosis and caspase-3-
ctivation (11,24). Activation of the Stat transcription-
athway augments host-cell antiviral systems and protects
gainst Coxsackie B3 myocarditis (19). This likely explains
he cardioprotection observed here with rhNRG-1, because
lthough NRG-1/erbB-mediated Stat-activation has not
et been demonstrated in myocardial cells, it has in other
ells; a response involving recruitment of Src to NRG-1-
romoted erbB/Stat complexes rather than erbB-mediated
ak-activation (25).
The finding that rhNRG-1 improved function and sur-
ival in the rat infarct model, even when the start of therapy
as delayed for 2 months, has important implications for
he clinical management of heart failure, where myocardial-
ell damage might already be advanced. Moreover, given
hat rhNRG-1 largely prevented rather than merely atten-
ated the deleterious cardiac effects of doxorubicin and
oxsackie B3, it might also be more efficacious in the
etting of ischemic heart disease, if treatment is not delayed
fter the onset of a myocardial infarct.
These considerations, coupled with the finding that
hNRG-1 improves cardiac function despite continued
acing in dogs with pacing-induced heart failure, suggest
hat its key action in all these disorders is improved integrity
nd performance of surviving cardiomyocytes. Given that
urvival is a “hard” end point for any therapeutic and given
hat the cardiac performance and survival benefits of
hNRG-1 were additive to those of angiotensin-converting
nzyme inhibitor therapy, the findings of the present study
uger well for the development of erbB-activation as a novel
nd potentially powerful approach to the treatment of a
ariety of common forms of heart failure.
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